AKT1 and acute myeloid leukemia: Hence, therapeutic targeting of DDR and PI3K/AKT signaling pathways alone or in combination with current standard AML chemotherapy and HMAs stands out as a potential strategy to overcome resistance and improve clinical outcome of AML patients.